| Trial ID: | L2217 |
| Source ID: | NCT05452525
|
| Associated Drug: |
Ckd-379 I
|
| Title: |
Pharmacokinetics and Safety/Tolerability Profile of CKD-379
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type II Diabetes Mellitus
|
| Interventions: |
DRUG: CKD-379 I|DRUG: CKD-379 II|DRUG: D759+D745+D150
|
| Outcome Measures: |
Primary: Cmax, Maximum plasma concentration of the drug, 0~48hours|AUClast, Area under the concentration-time curve from the time of dosing to the last measurable concentration, 0~48hours |
|
| Sponsor/Collaborators: |
Sponsor: Chong Kun Dang Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-07-26
|
| Completion Date: |
2022-09-21
|
| Results First Posted: |
|
| Last Update Posted: |
2022-10-18
|
| Locations: |
Seoul National University Hospital, Seoul, Jongno-gu, 03080, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT05452525
|
